Solutions

Online Inquiry

* Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Epibulbar Dermoid

A focused broad approach which includes top-notch genetic screening and novel therapeutics development is required to formulate successful strategies for the diagnostics and therapeutics of epibulbar dermoids. Protheragen leads this pioneer's charge, delivering unparalleled therapeutic development services.

Overview of Epibulbar Dermoid

Epibulbar dermoids are developmental cysts located on the conjunctival portion of the sclera which is a form of ocular dermoids. They represent a relatively common ocular surface abnormality that may be unilateral or bilateral and of variable size ranging from small to large. Epibulbar dermoids sometimes accompany more complex syndromes like Goldenhar syndrome which is characterized by other anomalies such as preauricular tags, facial asymmetry, and other craniofacial deformities.

Epibulbar dermoids are solid congenital choristomas, while epibulbar dermoid cysts represent their cystic variant, formed when ectodermal tissues become trapped during embryogenesis. Cystic lesions are lined by keratinizing squamous epithelium and contain adnexal structures including hair follicles, sweat glands and sebaceous glands. Approximately 70 % of cysttype cases are diagnosed in children under five years of age, though adultonset presentations also occur.

Prediction of the three-dimensional structure of PTCH1 protein.

Fig.1 The 3D structure of the PTCH1 protein predicted using the SWISS-MODEL. (Naveed M., et al., 2024)

Combined factors such as genetic mutation and abortion of embryonic processes are the impetus for epibulbar dermoid disease. Important to note is the mutation within the Patched 1 (PTCH1) gene which is responsible for the receptor protein of the Hedgehog signaling path. Embryonic development of tissue necessitates the coordination of a multitude of events and this specific pathway is one such integral event.

Diagnostics Development for Epibulbar Dermoid

Genetic Testing

Research is now increasingly concentrating on pathogenic alterations associated with the PTCH1 gene as part of genetic study of epibulbar dermoid. The mutations serve to explain the diagnosis as well as to illuminate some of the genetic construction of the condition. For patients suspected of associated systemic syndromes such as Goldenhar syndrome, genetic testing may identify relevant chromosomal aberrations.

Histopathological Examination

The diagnosis of epibulbar dermoid is definitive through histopathological examination of the biopsy specimens. Analysis under the microscope displays the presence of skin components amongst other features. This method is very effective in complicated cases that are difficult to interpret. Histopathology also distinguishes solid epibulbar dermoid from its cystic variant by identifying cyst-lining epithelium and cutaneous adnexal structures within cyst-type specimens.

Therapeutics Development for Epibulbar Dermoid

Artificial Intelligence (AI)-Assisted Drug Design
The innovation brought forward in AI is invaluable to the design of drugs for epibulbar dermoid. New therapeutic compounds targeting the PTCH1 protein have been developed from natural molecules like Fisetin using AI platforms like WADDAICA. These compounds are highly potent, low in toxicity, and have a latitude of promise as non-invasive therapeutics.
Phytochemicals
Fisetin and a range of phytochemicals have been studied for their possible therapeutics of epibulbar dermoid. These compounds possess anti-inflammation, anti-oxidation, and anti-proliferation activities which can help mitigate cell signaling pathways associated with the formation of dermoid cysts. Fisetin, which occurs in Neolamarckia cadamba and other plants, has shown an ability to interfere with the Hedgehog signaling pathway which seems to curb the growth of dermoid cells.

Therapeutics	Target	Description	Research Stage
Topical Corticosteroids	Inflammation	Used post-surgery to reduce inflammation and prevent scarring. Commonly includes dexamethasone or prednisolone.	Approved
Topical Antibiotics	Infection Prevention	Administered post-surgery to prevent bacterial infections. Examples include tobramycin and erythromycin.	Approved
Stem Cell Therapy	Tissue Regeneration	Explores the use of stem cells to regenerate damaged ocular tissues after cyst excision.	Preclinical
Anti-VEGF Agents	Angiogenesis	Investigated for their potential to inhibit abnormal blood vessel growth associated with cysts. Examples include bevacizumab.	Discovery
Wnt Pathway Inhibitors	Wnt Signaling Pathway	Targeting Wnt signaling, which is implicated in the pathogenesis of dermoid cysts. Examples include LGK974.	Discovery
BMP Pathway Modulators	BMP Signaling Pathway	Investigational therapies are aimed at modulating BMP signaling to prevent abnormal tissue development.	Discovery

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen provides a complete service package focused on diagnostics and therapeutic development for epibulbar dermoid. We cover the entire process of genetic consulting, histopathological study, and the development and verification of new therapeutic agents with the use of AI and phytochemicals.

Diagnostics Development

Therapeutic Development

Preclinical Research

Disease Models

Spontaneous Epibulbar Dermoid Canine Models
PTCH1 Mutation Rodent Models
Dermoid Tissue Implantation Rabbit Models
Genetic Engineering Non-Human Primate Models
OXL2 Mutant Mouse Models
Wnt1‑Cre Transgenic Mice Models
Human Dermoid Cyst Xenograft Models

Protheragen conducts rigorous preclinical testing of novel therapies, including gene and stem cell therapies, using animal models of epibulbar dermoid. If you are interested in our services, please feel free to contact us.

References

Naveed, Muhammad, et al. "Comparative toxicity assessment of fisetin-aided artificial intelligence-assisted drug design targeting epibulbar dermoid through phytochemicals." Open Chemistry 22.1 (2024): 20230197.
Choudhary, Dharamveer Singh, et al. "Massive corneal-epibulbar dermoid managed with pre-descemetic DALK and SLET." GMS Ophthalmology Cases 11 (2021).
Kaouani, Amine, et al. "Management of a giant ocular epibulbar dermoid." Journal of Pediatric Surgery Case Reports 71 (2021): 101944.
Lakhani, Dhairya A., Meaghan O. Morris, and Francis Deng. "Intracranial Epibulbar Dermoid Cyst." Radiology 311.1 (2024): e232952.
Choi, June Seok, et al. "Epibulbar Dermoid Cysts: epidemiology and diagnostic approach based on clinical experiences." Archives of Plastic Surgery 45.06 (2018): 512-516.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.